{{Rsnum
|rsid=2301159
|Gene=SLC10A2
|Chromosome=13
|position=103045378
|Orientation=minus
|GMAF=0.2824
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC10A2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 72.1 | 23.4 | 4.5
| HCB | 51.8 | 40.9 | 7.3
| JPT | 48.7 | 42.5 | 8.8
| YRI | 43.2 | 45.2 | 11.6
| ASW | 45.6 | 36.8 | 17.5
| CHB | 51.8 | 40.9 | 7.3
| CHD | 49.0 | 47.1 | 3.8
| GIH | 64.6 | 30.3 | 5.1
| LWK | 37.4 | 45.8 | 16.8
| MEX | 58.6 | 37.9 | 3.4
| MKK | 34.2 | 47.1 | 18.7
| TSI | 58.8 | 33.3 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2301159
|Name_s=SLC10A2:rs2301159 C>T; NM_000452.2:c.*755C>T
|Gene_s=SLC10A2
|Feature=3' UTR
|Evidence=PubMed ID:20038957
|Annotation=Risk or phenotype-associated allele: T Phenotype: The SLC10A2:rs2301159 T variant was associated with toxicity in response to docetaxel and thalidomide. Study size: 47 Study population/ethnicity: Patients diagnosed with castration-resistant prostate cancer enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. Significance metric(s): p = 0.01 Type of association: CO; TOX
|Drugs=docetaxel; thalidomide
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165111542
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2301159
|overall_frequency_n=33
|overall_frequency_d=128
|overall_frequency=0.257812
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}